Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
about
Specific small molecule inhibitors of Skp2-mediated p27 degradationThe 26S proteasome is a multifaceted target for anti-cancer therapiesElucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibitionClinical use of proteasome inhibitors in the treatment of multiple myelomaBortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouseChemotherapy-induced neuropathies-a growing problem for patients and health care providersMitotoxicity in distal symmetrical sensory peripheral neuropathiesCase Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyBortezomib use in a pediatric cardiac transplant center.Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyPhase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Proteasome inhibitors in glioblastomaBortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Pain in cancer survivorsElectroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Nurse self-evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with cancer.Proteasome inhibition and its therapeutic potential in multiple myelomaSchwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathyBortezomib in the management of multiple myeloma.Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma ModelProteasome inhibitors in the treatment of multiple myelomaOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphomaBortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceClinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaAcupuncture treatment for bortezomib-induced peripheral neuropathy: a case reportPilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.Herpes zoster complicating bortezomib therapy.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas.A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice.CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.
P2860
Q24596988-F9173259-1A58-4705-9BA4-916493794DABQ26795764-BEB01911-2265-4ABC-B474-65EE0D46C48DQ27666372-54836AC8-5A9F-46FC-9D19-B36194329AF3Q28080999-F9C23770-94E8-4E1D-8CFB-737C4E865500Q28533426-13C2A765-724D-4D4A-8E82-16B4936AAA8DQ28818565-D17A437D-2D9B-43E5-B658-0646753067ABQ28834071-84D91687-9123-41A0-904D-1606C468A6A7Q31050273-54AE1598-1B99-4B9F-8606-F67AF10C7545Q33393257-D693AC32-63CA-4312-BBE6-687C477F6BBAQ33397376-EA2D0F01-4638-40BE-96A7-CC179AA2243EQ33405602-259CC276-66CA-488B-95BC-09D0A43401F5Q33415926-A45CDDFB-3A79-4F16-8DC7-BE2839DE2083Q33422017-628D31B2-7876-4869-896C-A47F103E3815Q33437811-8F9C480D-31CD-4871-BC93-2DC12644E48EQ33598931-A3D15859-692B-4CB4-9EEF-A4DE1C91C5DDQ33617012-961A61B4-38BB-45B1-8FA5-ABEF5C0E9AF8Q33632270-34BE5B38-2B72-4666-AF2C-6FA753DE00A6Q33650576-3E477987-4BF9-4A73-877C-C63189B9D36BQ33684190-8D3DB225-4597-4B15-9900-3874513BC547Q33743023-8197D8D7-3115-4182-91B0-68BBB70253FFQ33882390-DFCE2384-1DEE-4E08-AF1F-CB72E2E34A16Q33885675-FEC1F91C-3E48-4B05-9453-C06734FD2956Q34343036-1567FB2E-4CC0-47F8-94E9-76822E0DE994Q34344053-1BE874FB-509F-4099-9F2A-A2B92288B1AEQ34418462-D292203B-6154-4853-B33D-12A74F35A2F0Q34478543-DB2E83AB-86B8-40AD-BC6F-EF4D390F8629Q34611676-9CCC6694-539F-489B-AC57-35888C494F72Q34788381-5BDD86DE-3ED7-4FBB-BB54-198880C173FDQ35050501-FAE16617-A1B3-47DD-833B-7C4B605E80F3Q35070412-5877D159-F942-4B02-BF21-4FA947566984Q35097338-624E0F66-1038-47B3-B98F-577645D35A4CQ35428713-08847B75-7015-4838-837F-D9B0F608DFC2Q35510549-7387AD5A-0A0F-4CCD-B423-CDAA41FA4C1BQ35551777-F3211E4A-3AE7-446B-BE4B-4312DC7405A0Q35564676-5C5BF531-361E-49A3-B1C2-59E64F8A4B9CQ35802414-371EE72D-CD4D-4315-9C6C-9C00DC02762FQ35865594-BCC489A1-438C-4649-AB91-F3341E4FC783Q36037229-47309A5D-F295-4FA3-A11F-ECA0529B576FQ36075303-6DE470B0-3E7C-4EE9-844D-B841DD52544BQ36084704-FC0B4DE1-0E7B-4DA5-82F8-64E6AC84BDF3
P2860
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bortezomib-induced peripheral ...... sive review of the literature.
@en
Bortezomib-induced peripheral ...... sive review of the literature.
@nl
type
label
Bortezomib-induced peripheral ...... sive review of the literature.
@en
Bortezomib-induced peripheral ...... sive review of the literature.
@nl
prefLabel
Bortezomib-induced peripheral ...... sive review of the literature.
@en
Bortezomib-induced peripheral ...... sive review of the literature.
@nl
P2093
P1433
P1476
Bortezomib-induced peripheral ...... sive review of the literature.
@en
P2093
Andreas A Argyriou
Gregoris Iconomou
Haralabos P Kalofonos
P304
P356
10.1182/BLOOD-2008-04-149385
P407
P577
2008-06-23T00:00:00Z